Nevertheless, some researchers recently engineered CAR-T cells using the variable fragments of a novel monoclonal antibody, TAB004, which specifically binds the tumor-associated-MUC1 (tMUC1) to PDA cells, showing promising cytotoxic activity [121]. This evidence concerns the gene MUC1 and neoplasm.